NBTX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Nanobiotix reported complete Phase 1 full-cohort results for JNJ-1900 (NBTXR3) in inoperable recurrent non-small cell lung cancerSep 14, 2026
- Nanobiotix announced a protocol amendment in its ongoing global Phase 3 head and neck cancer studyMay 5, 2026
- Nanobiotix presented first data from a randomized Phase 2 trial of JNJ-1900 in stage 3 inoperable lung cancerMar 30, 2026
- NANOBIOTIX announces new results from Phase 1 study evaluating JNJ-1900 (NBTXR3) in combination with immune checkpoint inhibitors as 2L+ therapy for patients with primary cutaneous melanoma resistant to anti-PD-1Sep 18, 2025